Randomised Phase III Trials With Large Patient Groups

We conduct randomised Phase III trials with large populations and a broad spectrum of therapy areas.

Our model is meticulously designed to cater to the specific requirements of our esteemed sponsors during the advanced stages of drug development.

x

Examples of Richmond’s accelerated patient recruitment

Leading the way among 83 centres, Richmond achieved top patient recruitment for a study focused on individuals with Transthyretin Amyloidosis with Cardiomyopathy, enrolling an impressive 64 patients within a three-month timeframe.

Richmond swiftly contributed to a global heart failure trial by successfully recruiting 10% of the total patient volunteers required within an exceptionally brief span of two months.

Experts In Conducting Randomised Phase III Clinical Trials.

Our specialist clinical team has experience in conducting clinical trials with a broad spectrum of patient groups with common and rare diseases.

Get in touch today

Why Choose Richmond Pharmacology For Phase III Clinical Trials?

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Single Centre Studies

We are equipped to deliver single centre studies for early phase patient trials.

Read more +

Multi-disciplined teams

Through our strategic collaborations with academic institutions and medical organisations, we have established invaluable connections with a network of esteemed specialist consultants, professors, and skilled medical practitioners.

Read more +

Hospital-style setting

Our multi-disciplinary team operates in a hospital-style setting which facilitates efficient, safe trial management. 

Read more +

Our patient retention rate remains at an exceptional 100%, a testament to the dedication and responsiveness of our volunteer recruitment project managers.

Latest news

PATIENT WITH RARE BLEEDING DISORDER BECOMES FIRST TO TEST NEW TREATMENT

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event